MADISON, Wis.--(BUSINESS WIRE)--NeuroPointDX, a division of Stemina Biomarker Discovery, today announced the appointment of E. Robert Wassman, M.D. as Medical Director. Dr. Wassman has pioneered the introduction of personalized medicine approaches and the delivery of cutting-edge diagnostic technology to clinical medicine for over 35 years, including genetic testing for autism spectrum disorder (ASD) and other neurodevelopmental conditions.
“Bob Wassman is an experienced clinician, diagnostics developer, and industry leader in bringing precision medicine approaches to the field of neurodevelopmental medicine, and specifically autism spectrum disorder,” said Elizabeth Donley, President and Chief Executive Officer of Stemina. “His combination of medical knowledge, diagnostics development expertise, and business experience will be an outstanding resource for NeuroPointDX as we continue our efforts to bring precision medicine approaches based on metabolomics to ASD and other neurological conditions.”
Dr. Wassman has served as Chief Medical Officer (CMO) for multiple companies in the genetic testing, biomarker discovery, and diagnostics development space and has served as an expert consultant to entities ranging from large and small clinical laboratories, in vitro diagnostics and biotechnology companies, and others. From 2015 to 2017, he was CMO of Lineagen, Inc., a company focused on genetic testing for ASD and developmental delay.
“I look forward to working with NeuroPointDX to provide earlier diagnosis and insight into more precise treatment options for children and families living with ASD,” said Dr. Wassman. “The company’s clinical validation of the first metabolism-based autism diagnostic test panel, in the context of the largest study of the metabolism of children with ASD conducted to-date, demonstrates that NeuroPointDX’s approach offers the precision to understand more about the underlying metabolism of children with ASD.”
In addition to his service at Lineagen, Dr. Wassman was CMO at Rosetta Genomics from 2012 to 2015, where he was responsible for all medical operations and external communications to clients, payers, and medical-scientific community. He has also served as CMO at other companies in the personalized medicine space including Genzyme Genetics, Celula, Ambry Genetics, and Alfigen. He is a graduate of Yale University and Albany Medical College, and Board Certified in Pediatrics and Medical Genetics.
“I am very pleased to join NeuroPointDX in their efforts to bring precision medicine to autism spectrum disorder and other neurological conditions that are sorely in need of better methods of diagnosis and treatment,” said Dr. Wassman. “NeuroPointDX’s metabolomics focus brings and important perspective to this field, based on its ability to identify potentially actionable approaches to these complex medical conditions which research suggests are affected by a variety of factors beyond genetics.”
NeuroPointDX, a division of Stemina Biomarker Discovery, is bringing a precision medicine approach to the diagnosis and treatment of neurological disorders through the application of world-class metabolomics. The company’s current focus is autism spectrum disorder (ASD). NeuroPointDX has developed and is commercializing a new ASD diagnostic test through its CLIA-certified laboratory.
The NPDX AA test identifies children with metabolic subtypes associated with ASD. The test may be used to screen children as young as 18 months. The NPDX AA test also provides metabolic information that may be used to inform a more precise treatment strategy for a child with ASD. The metabolic subtypes were identified and validated in children 18-48 months old in the largest clinical study of metabolism of children with ASD conducted to date, the Children’s Autism Metabolome Project (CAMP). For more information, please visit our website at http://www.NeuroPointDX.com.